About
Zeta Therapeutics
Smart nanotechnology finding new solutions to old problems
Zeta Therapeutics
Smart nanotechnology finding new solutions to old problems
About Zeta
Zeta Therapeutics is a Sydney based life sciences company established in 2018 to focus on the commercial development of new treatments for cancer and other serious diseases based on its unique nanotechnology platform. Zeta’s core technology has been developed by researchers at the University of Sydney over many years of collaboration and support by government and industry partners. The flexibility of the technology platform enables nanoparticles to be configured to provide unprecedented levels of biological compatibility and therapeutic effectiveness. Whilst we have identified a number of promising medical applications for the technology, the focus of Zeta’s first product, ZTX018, will be to improve treatment outcomes for women diagnosed with ovarian cancer.
About Zeta
Zeta Therapeutics is a Sydney based life sciences company established in 2018 to focus on the commercial development of new treatments for cancer and other serious diseases based on its unique nanotechnology platform. Zeta’s core technology has been developed by researchers at the University of Sydney over many years of collaboration and support by government and industry partners. The flexibility of the technology platform enables nanoparticles to be configured to provide unprecedented levels of biological compatibility and therapeutic effectiveness. Whilst we have identified a number of promising medical applications for the technology, the focus of Zeta’s first product, ZTX018, will be to improve treatment outcomes for women diagnosed with ovarian cancer.
About Zeta
Zeta Therapeutics is a Sydney based life sciences company established in 2018 to focus on the commercial development of new treatments for cancer and other serious diseases based on its unique nanotechnology platform. Zeta’s core technology has been developed by researchers at the University of Sydney over many years of collaboration and support by government and industry partners. The flexibility of the technology platform enables nanoparticles to be configured to provide unprecedented levels of biological compatibility and therapeutic effectiveness. Whilst we have identified a number of promising medical applications for the technology, the focus of Zeta’s first product, ZTX018, will be to improve treatment outcomes for women diagnosed with ovarian cancer.
Dr Steve Jones
Founder And Managing Director
Slide title
Write your caption hereButton
Steve is the founder and Managing Director of Zeta Therapeutics with 30 years experience in cancer research in both academia and industry. Steve brings particular expertise in small particle technologies, microspheres and nanoparticles, applied to the development of innovative medical therapies. After completing a PhD in physics at the University of Western Australia in 1988, Steve chose to focus on medical research, joining the group that eventually went on to found Sirtex Medical, an Australian life sciences company that rose from humble startup to an ASX100 company before eventually being acquired by a Chinese consortium. From 2005 to 2017 he was Global Head of R&D at Sirtex during which time he managed a range of new product developments, was involved in new technology sourcing and evaluation, managed the company IP portfolio as well as negotiating licencing and research contracts with Australian and international research institutions.
Dr Steve Jones
Founder And Managing Director
-
Slide title
Write your caption hereButton
Steve is the founder and Managing Director of Zeta Therapeutics with 30 years experience in cancer research in both academia and industry. Steve brings particular expertise in small particle technologies, microspheres and nanoparticles, applied to the development of innovative medical therapies. After completing a PhD in physics at the University of Western Australia in 1988, Steve chose to focus on medical research, joining the group that eventually went on to found Sirtex Medical, an Australian life sciences company that rose from humble startup to an ASX100 company before eventually being acquired by a Chinese consortium. From 2005 to 2017 he was Global Head of R&D at Sirtex during which time he managed a range of new product developments, was involved in new technology sourcing and evaluation, managed the company IP portfolio as well as negotiating licensing and research contracts with Australian and international research institutions.
Dr Steve Jones
Founder And Managing Director
-
Slide title
Write your caption hereButton
Steve is the founder and Managing Director of Zeta Therapeutics with 30 years experience in cancer research in both academia and industry. Steve brings particular expertise in small particle technologies, microspheres and nanoparticles, applied to the development of innovative medical therapies. After completing a PhD in physics at the University of Western Australia in 1988, Steve chose to focus on medical research, joining the group that eventually went on to found Sirtex Medical, an Australian life sciences company that rose from humble startup to an ASX100 company before eventually being acquired by a Chinese consortium. From 2005 to 2017 he was Global Head of R&D at Sirtex during which time he managed a range of new product developments, was involved in new technology sourcing and evaluation, managed the company IP portfolio as well as negotiating licencing and research contracts with Australian and international research institutions.
